Carderock Capital Management Inc. Purchases 3,362 Shares of Danaher Corporation $DHR

Carderock Capital Management Inc. increased its position in shares of Danaher Corporation (NYSE:DHR) by 15.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,465 shares of the conglomerate’s stock after buying an additional 3,362 shares during the period. Carderock Capital Management Inc.’s holdings in Danaher were worth $5,601,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new position in shares of Danaher in the 3rd quarter valued at about $25,000. WFA of San Diego LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $26,000. Howard Hughes Medical Institute bought a new stake in shares of Danaher in the 2nd quarter valued at about $27,000. ANTIPODES PARTNERS Ltd acquired a new stake in Danaher in the 3rd quarter valued at about $27,000. Finally, TruNorth Capital Management LLC bought a new position in Danaher during the third quarter worth about $28,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the sale, the executive vice president directly owned 5,099 shares in the company, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.20% of the company’s stock.

Danaher Stock Up 0.4%

DHR opened at $190.05 on Tuesday. The stock has a fifty day moving average of $213.35 and a 200-day moving average of $214.97. The company has a market capitalization of $134.39 billion, a P/E ratio of 37.71, a P/E/G ratio of 2.57 and a beta of 0.93. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $242.80. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.51 and a current ratio of 1.87.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The business had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.79 billion. During the same period last year, the firm earned $2.14 earnings per share. Danaher’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.40 per share. This is a boost from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s payout ratio is 25.40%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. KeyCorp reissued an “overweight” rating on shares of Danaher in a research report on Thursday, January 29th. Leerink Partners raised their price objective on Danaher from $260.00 to $270.00 and gave the company an “outperform” rating in a research report on Friday, January 16th. The Goldman Sachs Group reduced their target price on Danaher from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Danaher in a research report on Thursday, January 29th. Finally, TD Cowen reiterated a “buy” rating on shares of Danaher in a research note on Wednesday, January 7th. Nineteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $253.55.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.